The endocannabinoid system in glial cells and their profitable interactions to treat epilepsy: Evidence from animal models
| dc.contributor.author | Egaña-Huguet, Jon | |
| dc.contributor.author | Soria-Gómez, Edgar | |
| dc.contributor.author | Grandes, Pedro | |
| dc.date.accessioned | 2022-11-17T00:15:57Z | |
| dc.date.available | 2022-11-17T00:15:57Z | |
| dc.date.copyright | 2021 | en_US |
| dc.date.issued | 2021 | |
| dc.description.abstract | Epilepsy is one of the most common neurological conditions. Yearly, five million people are diagnosed with epileptic-related disorders. The neuroprotective and therapeutic effect of (endo)cannabinoid compounds has been extensively investigated in several models of epilepsy. Therefore, the study of specific cell-type-dependent mechanisms underlying cannabinoid effects is crucial to understanding epileptic disorders. It is estimated that about 100 billion neurons and a roughly equal number of glial cells co-exist in the human brain. The glial population is in charge of neuronal viability, and therefore, their participation in brain pathophysiology is crucial. Furthermore, glial malfunctioning occurs in a wide range of neurological disorders. However, little is known about the impact of the endocannabinoid system (ECS) regulation over glial cells, even less in pathological conditions such as epilepsy. In this review, we aim to compile the existing knowledge on the role of the ECS in different cell types, with a particular emphasis on glial cells and their impact on epilepsy. Thus, we propose that glial cells could be a novel target for cannabinoid agents for treating the etiology of epilepsy and managing seizure-like disorders. | en_US |
| dc.description.reviewstatus | Reviewed | en_US |
| dc.description.scholarlevel | Faculty | en_US |
| dc.description.sponsorship | This work was supported by the Basque Government (IT1230-19, to P.G.); MINECO/FEDER, UE (SAF2015-65034-R, to P.G.); Ministry of Science and Innovation (PID2019-107548RBI00, to P.G.); Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU, Investing in your future; RD16/0017/0012, to P.G.); J.E.-H. is a Postdoctoral Researcher contracted with funds of Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III) and European Regional Development Funds-European Union (ERDF-EU, Investing in your future; RD16/0017/0012), and the Basque Government (IT1230-19). E.S.-G. is funded by Ikerbasque and MINECO (PGC2018-093990-A-I00; MICIU/AEI/FEDER, UE). | en_US |
| dc.identifier.citation | Egaña-Huguet, J., Soria-Gómez, E., & Grandes, P. (2021). “The endocannabinoid system in glial cells and their profitable interactions to treat epilepsy: Evidence from animal models.” International Journal of Molecular Sciences, 22(24), 13231. https://doi.org/10.3390/ijms222413231 | en_US |
| dc.identifier.uri | https://doi.org/10.3390/ijms222413231 | |
| dc.identifier.uri | http://hdl.handle.net/1828/14483 | |
| dc.language.iso | en | en_US |
| dc.publisher | International Journal of Molecular Sciences | en_US |
| dc.subject | endocannabinoid system | |
| dc.subject | glial cells | |
| dc.subject | epilepsy | |
| dc.subject | neuroinflammation | |
| dc.subject.department | Division of Medical Sciences | |
| dc.subject.department | School of Medical Sciences | |
| dc.title | The endocannabinoid system in glial cells and their profitable interactions to treat epilepsy: Evidence from animal models | en_US |
| dc.type | Article | en_US |